Literature DB >> 24876522

CLL and NHL: the end of chemotherapy?

Bruce D Cheson1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24876522     DOI： 10.1182/blood-2014-04-563890

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Authors:  David M Lucas; Amy S Ruppert; Gerard Lozanski; Gordon W Dewald; Arletta Lozanski; Rainer Claus; Christoph Plass; Ian W Flinn; Donna S Neuberg; Elisabeth M Paietta; John M Bennett; Diane F Jelinek; John G Gribben; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Dennis F Moore; Martin S Tallman; John C Byrd; Michael R Grever
Journal:  Leuk Lymphoma       Date:  2015-03-30

Review 2.  Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

Authors:  Oluwatobi O Ozoya; Julio Chavez; Lubomir Sokol; Samir Dalia
Journal:  Ann Transl Med       Date:  2017-02

3.  Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.

Authors:  Tracy C Okoli; Cody J Peer; Kieron Dunleavy; William D Figg
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 4.  Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies.

Authors:  Oluwatobi O Ozoya; Lubomir Sokol; Samir Dalia
Journal:  J Clin Transl Hepatol       Date:  2016-06-15

Review 5.  The B cell receptor signaling pathway in mantle cell lymphoma.

Authors:  Maria I Merolle; Makhdum Ahmed; Krystle Nomie; Michael L Wang
Journal:  Oncotarget       Date:  2018-03-27

6.  Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.

Authors:  Eungyoung Kim; Jehyun Nam; Woochul Chang; Ismayil S Zulfugarov; Zhanna M Okhlopkova; Daniil Olennikov; Nadezhda K Chirikova; Sang-Woo Kim
Journal:  Sci Rep       Date:  2018-07-12       Impact factor: 4.379

Review 7.  Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.

Authors:  Andrew Davies; Claude Berge; Axel Boehnke; Anjum Dadabhoy; Pieternella Lugtenburg; Simon Rule; Mathias Rummel; Christine McIntyre; Rodney Smith; Xavier Badoux
Journal:  Adv Ther       Date:  2017-10-05       Impact factor: 3.845
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.